Skip to main content Skip to search
Biodegradable Gelatin Methacryloyl Microneedles for Transdermal Drug Delivery
ADHM Advanced Healthcare Materials
Format: Journal Article
Publication Year: 2019
Source ID: shanti-sources-105506
Abstract: Biocompatible and bioresponsive microneedles (MNs) are emerging technology platforms for sustained drug release with a potential to be a key player in transdermal delivery of therapeutics. In this paper, an innovative biodegradable MNs patch for the sustained delivery of drugs using a polymer patch, which can adjust delivery rates based on its crosslinking degree, is reported. Gelatin methacryloyl (GelMA) is used as the base for engineering biodegradable MNs. The anticancer drug doxorubicin (DOX) is loaded into GelMA MNs using the one molding step. The GelMA MNs can efficiently penetrate the stratum corneum layer of a mouse cadaver skin. Mechanical properties and drug release behavior of the GelMA MNs can be adjusted by tuning the degree of crosslinking. The efficacy of the DOX released from the GelMA MNs is tested and the anticancer efficacy of the released drugs against melanoma cell line A375 is demonstrated. Since GelMA is a versatile material in engineering tissue scaffolds, it is expected that the GelMA MNs can be used as a platform for the delivery of various therapeutics.
A biocompatible and biodegradable microneedles patch based on gelatin methacryloyl are developed for transcutaneous delivery of drugs. The microneedles can efficiently penetrate the stratum corneum layer in a mouse cadaver skin model and the drug release profile can be controlled by tuning the crosslinking degrees. The model drug doxorubicin keeps its anticancer efficacy after enzyme-mediated release from the patch.